Clinical Trials for Ascentage Pharma

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

A Study of Olverembatinib in SDH-deficient GIST.

A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus.

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Global Trial in APG2575 for Patients With CLL/SLL

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

APG-115 in Salivary Gland Cancer Trial

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

APG-2449 in Patients With Advanced Solid Tumors

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

A Study of HQP1351 in Patients With GIST or Other Solid Tumors